Birdwatch Note
2023-04-21 16:07:52 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Ivermectin tablets are approved by the FDA to treat people with intestinal strongyloidiasis and onchocerciasis, two conditions caused by parasitic worms. Randomized controlled trials show Ivermectin does not have efficacy in COVID-19, cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://www.reuters.com/article/factcheck-nobel-ivermectin/fact-check-2015-nobel-prize-for-ivermectin-intended-for-treatment-of-parasitic-infections-doesnt-prove-its-efficacy-on-covid-19-idUSL1N2QB2XA https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362 https://jamanetwork.com/journals/jama/fullarticle/2777389 https://www.nejm.org/doi/full/10.1056/NEJMoa2115869 https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
Written by 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1649436237416087552
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1649444853502164997
- noteId - 1649444853502164997
- participantId -
- noteAuthorParticipantId - 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31 Participant Details
- createdAtMillis - 1682093272936
- tweetId - 1649436237416087552
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Ivermectin tablets are approved by the FDA to treat people with intestinal strongyloidiasis and onchocerciasis, two conditions caused by parasitic worms. Randomized controlled trials show Ivermectin does not have efficacy in COVID-19, cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://www.reuters.com/article/factcheck-nobel-ivermectin/fact-check-2015-nobel-prize-for-ivermectin-intended-for-treatment-of-parasitic-infections-doesnt-prove-its-efficacy-on-covid-19-idUSL1N2QB2XA https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362 https://jamanetwork.com/journals/jama/fullarticle/2777389 https://www.nejm.org/doi/full/10.1056/NEJMoa2115869 https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
Note Ratings
rated at | rated by | |
2023-04-21 13:03:48 -0500 | Rating Details | |
2023-04-22 10:01:23 -0500 | Rating Details | |
2023-04-21 15:17:28 -0500 | Rating Details | |
2023-04-21 22:42:06 -0500 | Rating Details | |
2023-04-22 09:46:47 -0500 | Rating Details | |
2023-04-22 10:35:12 -0500 | Rating Details | |
2023-04-21 18:42:27 -0500 | Rating Details | |
2023-04-21 23:18:30 -0500 | Rating Details | |
2023-04-21 13:59:15 -0500 | Rating Details | |
2023-04-21 13:52:47 -0500 | Rating Details | |
2023-04-22 11:19:09 -0500 | Rating Details | |
2023-04-21 11:23:59 -0500 | Rating Details | |
2023-04-21 22:05:01 -0500 | Rating Details | |
2023-04-21 11:23:27 -0500 | Rating Details | |
2023-04-22 00:30:04 -0500 | Rating Details | |
2023-04-21 11:14:59 -0500 | Rating Details | |
2023-04-21 22:35:21 -0500 | Rating Details | |
2023-04-21 15:26:51 -0500 | Rating Details | |
2023-04-22 01:41:21 -0500 | Rating Details | |
2023-04-22 09:27:56 -0500 | Rating Details | |
2023-04-21 14:07:08 -0500 | Rating Details | |
2023-04-21 19:49:36 -0500 | Rating Details | |
2023-04-21 21:29:46 -0500 | Rating Details | |
2023-04-21 17:25:33 -0500 | Rating Details | |
2023-04-21 13:17:43 -0500 | Rating Details | |
2023-04-21 21:00:57 -0500 | Rating Details | |
2023-04-22 08:59:57 -0500 | Rating Details | |
2023-04-21 14:21:06 -0500 | Rating Details | |
2023-04-21 12:21:08 -0500 | Rating Details | |
2023-04-22 06:41:53 -0500 | Rating Details | |
2023-04-21 15:42:57 -0500 | Rating Details | |
2023-04-21 19:07:14 -0500 | Rating Details | |
2023-04-22 18:00:38 -0500 | Rating Details | |
2023-04-21 22:11:23 -0500 | Rating Details | |
2023-04-21 20:58:58 -0500 | Rating Details | |
2023-04-21 20:41:08 -0500 | Rating Details | |
2023-04-21 20:14:04 -0500 | Rating Details | |
2023-04-21 12:52:21 -0500 | Rating Details | |
2023-04-21 12:32:47 -0500 | Rating Details | |
2023-04-21 13:28:25 -0500 | Rating Details | |
2023-04-21 18:44:16 -0500 | Rating Details | |
2023-04-21 13:18:52 -0500 | Rating Details | |
2023-04-21 11:33:13 -0500 | Rating Details | |
2023-04-21 13:39:37 -0500 | Rating Details | |
2023-04-21 11:15:23 -0500 | Rating Details | |
2023-04-21 22:32:17 -0500 | Rating Details | |
2023-04-22 23:32:31 -0500 | Rating Details | |
2023-04-21 21:31:03 -0500 | Rating Details | |
2023-04-21 12:55:20 -0500 | Rating Details | |
2023-04-21 20:46:48 -0500 | Rating Details | |
2023-04-21 14:06:41 -0500 | Rating Details | |
2023-04-21 13:11:32 -0500 | Rating Details | |
2023-04-21 23:50:29 -0500 | Rating Details | |
2023-04-21 21:34:05 -0500 | Rating Details | |
2023-04-21 20:52:52 -0500 | Rating Details | |
2023-04-21 20:29:23 -0500 | Rating Details | |
2023-04-21 20:51:05 -0500 | Rating Details | |
2023-04-21 22:06:32 -0500 | Rating Details | |
2023-04-21 14:33:29 -0500 | Rating Details | |
2023-04-22 02:47:25 -0500 | Rating Details | |
2023-04-21 17:15:24 -0500 | Rating Details | |
2023-04-21 16:20:25 -0500 | Rating Details | |
2023-04-21 22:28:18 -0500 | Rating Details | |
2023-04-21 21:14:01 -0500 | Rating Details | |
2023-04-22 07:03:20 -0500 | Rating Details | |
2023-04-21 20:50:37 -0500 | Rating Details | |
2023-04-22 08:42:25 -0500 | Rating Details | |
2023-04-22 09:48:01 -0500 | Rating Details | |
2023-04-21 14:42:33 -0500 | Rating Details | |
2023-04-21 11:15:33 -0500 | Rating Details | |
2023-04-21 15:06:52 -0500 | Rating Details | |
2023-04-21 14:34:40 -0500 | Rating Details | |
2023-04-21 21:17:23 -0500 | Rating Details | |
2023-04-21 11:34:16 -0500 | Rating Details | |
2023-04-22 20:59:14 -0500 | Rating Details | |
2023-04-21 22:13:35 -0500 | Rating Details | |
2023-04-21 11:55:19 -0500 | Rating Details | |
2023-04-22 00:29:08 -0500 | Rating Details | |
2023-04-24 02:38:25 -0500 | Rating Details | |
2023-04-21 21:07:04 -0500 | Rating Details | |
2023-04-21 13:57:48 -0500 | Rating Details | |
2023-04-21 13:33:41 -0500 | Rating Details | |
2023-04-21 13:13:26 -0500 | Rating Details | |
2023-04-21 17:14:54 -0500 | Rating Details | |
2023-04-21 20:01:08 -0500 | Rating Details | |
2023-04-23 21:44:16 -0500 | Rating Details | |
2023-04-21 12:02:16 -0500 | Rating Details | |
2023-04-21 13:18:17 -0500 | Rating Details | |
2023-04-21 20:29:22 -0500 | Rating Details | |
2023-04-21 23:03:22 -0500 | Rating Details | |
2023-04-21 17:43:52 -0500 | Rating Details | |
2023-04-21 17:40:17 -0500 | Rating Details | |
2023-04-21 19:29:15 -0500 | Rating Details | |
2023-04-22 00:20:35 -0500 | Rating Details | |
2023-04-21 11:39:38 -0500 | Rating Details | |
2023-04-22 07:17:27 -0500 | Rating Details | |
2023-04-21 12:38:18 -0500 | Rating Details | |
2023-04-22 09:43:07 -0500 | Rating Details | |
2023-04-21 21:35:01 -0500 | Rating Details | |
2023-04-21 12:40:37 -0500 | Rating Details | |
2023-04-22 05:09:12 -0500 | Rating Details | |
2023-04-21 13:03:48 -0500 | Rating Details | |
2023-04-22 10:01:23 -0500 | Rating Details | |
2023-04-21 15:17:28 -0500 | Rating Details | |
2023-04-21 22:42:06 -0500 | Rating Details | |
2023-04-22 09:46:47 -0500 | Rating Details | |
2023-04-22 10:35:12 -0500 | Rating Details | |
2023-04-21 18:42:27 -0500 | Rating Details | |
2023-04-21 23:18:30 -0500 | Rating Details | |
2023-04-21 13:59:15 -0500 | Rating Details | |
2023-04-21 13:52:47 -0500 | Rating Details | |
2023-04-22 11:19:09 -0500 | Rating Details | |
2023-04-21 11:23:59 -0500 | Rating Details | |
2023-04-21 22:05:01 -0500 | Rating Details | |
2023-04-21 11:23:27 -0500 | Rating Details | |
2023-04-22 00:30:04 -0500 | Rating Details | |
2023-04-21 11:14:59 -0500 | Rating Details | |
2023-04-21 22:35:21 -0500 | Rating Details | |
2023-04-21 15:26:51 -0500 | Rating Details | |
2023-04-22 01:41:21 -0500 | Rating Details | |
2023-04-22 09:27:56 -0500 | Rating Details | |
2023-04-21 14:07:08 -0500 | Rating Details | |
2023-04-21 19:49:36 -0500 | Rating Details | |
2023-04-21 21:29:46 -0500 | Rating Details | |
2023-04-21 17:25:33 -0500 | Rating Details | |
2023-04-21 13:17:43 -0500 | Rating Details | |
2023-04-21 21:00:57 -0500 | Rating Details | |
2023-04-22 08:59:57 -0500 | Rating Details | |
2023-04-21 14:21:06 -0500 | Rating Details | |
2023-04-21 12:21:08 -0500 | Rating Details | |
2023-04-22 06:41:53 -0500 | Rating Details | |
2023-04-21 15:42:57 -0500 | Rating Details | |
2023-04-21 19:07:14 -0500 | Rating Details | |
2023-04-22 18:00:38 -0500 | Rating Details | |
2023-04-21 22:11:23 -0500 | Rating Details | |
2023-04-21 20:58:58 -0500 | Rating Details | |
2023-04-21 20:41:08 -0500 | Rating Details | |
2023-04-21 20:14:04 -0500 | Rating Details | |
2023-04-21 12:52:21 -0500 | Rating Details | |
2023-04-21 12:32:47 -0500 | Rating Details | |
2023-04-21 13:28:25 -0500 | Rating Details | |
2023-04-21 18:44:16 -0500 | Rating Details | |
2023-04-21 13:18:52 -0500 | Rating Details | |
2023-04-21 11:33:13 -0500 | Rating Details | |
2023-04-21 13:39:37 -0500 | Rating Details | |
2023-04-21 11:15:23 -0500 | Rating Details | |
2023-04-21 22:32:17 -0500 | Rating Details | |
2023-04-22 23:32:31 -0500 | Rating Details | |
2023-04-21 21:31:03 -0500 | Rating Details | |
2023-04-21 12:55:20 -0500 | Rating Details | |
2023-04-21 20:46:48 -0500 | Rating Details | |
2023-04-21 14:06:41 -0500 | Rating Details | |
2023-04-21 13:11:32 -0500 | Rating Details | |
2023-04-21 23:50:29 -0500 | Rating Details | |
2023-04-21 21:34:05 -0500 | Rating Details | |
2023-04-21 20:52:52 -0500 | Rating Details | |
2023-04-21 20:29:23 -0500 | Rating Details | |
2023-04-21 20:51:05 -0500 | Rating Details | |
2023-04-21 22:06:32 -0500 | Rating Details | |
2023-04-21 14:33:29 -0500 | Rating Details | |
2023-04-22 02:47:25 -0500 | Rating Details | |
2023-04-21 17:15:24 -0500 | Rating Details | |
2023-04-21 16:20:25 -0500 | Rating Details | |
2023-04-21 22:28:18 -0500 | Rating Details | |
2023-04-21 21:14:01 -0500 | Rating Details | |
2023-04-22 07:03:20 -0500 | Rating Details | |
2023-04-21 20:50:37 -0500 | Rating Details | |
2023-04-22 08:42:25 -0500 | Rating Details | |
2023-04-22 09:48:01 -0500 | Rating Details | |
2023-04-21 14:42:33 -0500 | Rating Details | |
2023-04-21 11:15:33 -0500 | Rating Details | |
2023-04-21 15:06:52 -0500 | Rating Details | |
2023-04-21 14:34:40 -0500 | Rating Details | |
2023-04-21 21:17:23 -0500 | Rating Details | |
2023-04-21 11:34:16 -0500 | Rating Details | |
2023-04-22 20:59:14 -0500 | Rating Details | |
2023-04-21 22:13:35 -0500 | Rating Details | |
2023-04-21 11:55:19 -0500 | Rating Details | |
2023-04-22 00:29:08 -0500 | Rating Details | |
2023-04-24 02:38:25 -0500 | Rating Details | |
2023-04-21 21:07:04 -0500 | Rating Details | |
2023-04-21 13:57:48 -0500 | Rating Details | |
2023-04-21 13:33:41 -0500 | Rating Details | |
2023-04-21 13:13:26 -0500 | Rating Details | |
2023-04-21 17:14:54 -0500 | Rating Details | |
2023-04-21 20:01:08 -0500 | Rating Details | |
2023-04-23 21:44:16 -0500 | Rating Details | |
2023-04-21 12:02:16 -0500 | Rating Details | |
2023-04-21 13:18:17 -0500 | Rating Details | |
2023-04-21 20:29:22 -0500 | Rating Details | |
2023-04-21 23:03:22 -0500 | Rating Details | |
2023-04-21 17:43:52 -0500 | Rating Details | |
2023-04-21 17:40:17 -0500 | Rating Details | |
2023-04-21 19:29:15 -0500 | Rating Details | |
2023-04-22 00:20:35 -0500 | Rating Details | |
2023-04-21 11:39:38 -0500 | Rating Details | |
2023-04-22 07:17:27 -0500 | Rating Details | |
2023-04-21 12:38:18 -0500 | Rating Details | |
2023-04-22 09:43:07 -0500 | Rating Details | |
2023-04-21 21:35:01 -0500 | Rating Details | |
2023-04-21 12:40:37 -0500 | Rating Details | |
2023-04-22 05:09:12 -0500 | Rating Details | |
2024-03-30 09:27:28 -0500 | Rating Details |